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In 1939 Osgood et al.1 reported infusing bone marrow into 
patients with severe aplastic anaemia without any clinical 
benefit. Rekers and Coulter2 attempted to reconstitute 
marrow function in irradiated dogs by marrow infusions. 
Both failed because of insufficient irradiation to produce 
immunosuppression necessary for engraftment. In 1957 
Donnall Thomas and co-workers3 showed that marrow 
can be collected, stored in significant quantities and safely 
administered. Marrow transplants remained unsuccessful, 
however, although patients with refractory leukaemia given 
supralethal irradiation recovered after marrow infusion 
from identical twins.4 Allogeneic marrow transplants usually 
resulted in failed engraftment, or engraftment followed by 
lethal graft-versus-host disease (GVHD). Further discoveries 
were the HLA complex and transplantation antigens,5 and that 
successful allogeneic engrafting depends upon donor/recipient 
histocompatibility.6 
These studies pointed the way for human marrow grafting 
using HLA-matched sibling donors. Thomas et al.4 showed that 
it was possible to cure leukaemia, aplastic anaemia, 
thalassaemia and inherited marrow disorders using a 
histocompatible sibling donor. The finding that methotrexate 
and subsequent immunosuppressive agents such as 
azathioprine, cyclosporine and tacrolimus, reduced GVHD as 
well as graft failure, improved results of marrow 
transplantation. 
Haematopoietic growth factors
The discovery of haematopoietic growth factors, granulocyte-
colony-stimulating factor (G-CSF) and granulocyte-
macrophage-colony-stimulating factor (GM-CSF) in the 1980s 
had a major impact on marrow transplantation. CSFs stimulate 
haematopoietic progenitor cells, permitting rapid proliferation 
and repopulation of marrow by engrafted cells.7 Recombinant 
DNA technology enabled CSFs to be synthesised for clinical 
use. 
The physiological effect of G-CSF in mobilisation of 
haematopoietic stem cells into peripheral blood enabled 
peripheral blood stem cell harvesting to replace marrow 
harvesting to obtain stem cells. A cell separator harvests stem 
cells from peripheral blood, obviating general anaesthesia to 
aspirate marrow.  Donors are given a 5-day course of 5 - 10 μg/
kg subcutaneous G-CSF before the stem cells are harvested. It 
takes 4 - 6 hours to obtain sufficient cells for the infusion. 
Graft-versus-host disease 
Although some early transplants were successful, problems 
occurred due to graft failure, rejection and acute GVHD. 
Some patients receiving marrow from siblings developed a 
potentially fatal syndrome of an erythematous desquamating 
rash, watery diarrhoea and jaundice. 
The most successful transplants, with minimal rejection 
and GVHD, are between identical twins, i.e. syngeneic 
transplantation. 
Immunosuppressive agents
Immunosuppression, first developed in renal transplantation, 
was then applied to marrow transplantation. Immunosuppressive 
agents included azathioprine, cyclosporine, antithymocyte 
globulin, antilymphocyte globulin and later tacrolimus, antiCD25 
(T-cell receptor) monoclonal antibodies basiliximab and 
dacluzumab, and mTOR (mammalian target of rapamycin) 
inhibitors, sirolimus and everolimus. 
Murine anti-CD52 monoclonal antibody, Campath-1G, 
when added to the harvested stem cells bag, removes almost 
all lymphoid cells, limiting GVHD although increasing the 
risk of leukaemia relapse. Humanised anti-CD52 monoclonal 
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stem cells, reduces murine protein anaphylactic reactions and 
the development of human anti-mouse antibodies (HAMA).8 
Graft-versus-leukaemia effect 
A major reason for success of allogeneic transplantation 
in myeloid and possible lymphoid malignancies was the 
suppressant effect of donor T lymphocytes and NK cells on 
the underlying malignancy. This graft-versus-leukaemia (GVL) 
effect has to be balanced against the risk of GVHD. Mild GVHD 
with GVL is ideal, whereas severe GVHD is undesirable. 
Patients receiving T-cell-depleted stem cells or syngeneic 
transplantation have a higher risk of relapse of their underlying 
disease.9 
Lack of sibling donors
As donors for an allogeneic stem cell transplant require an 
exact HLA Class I (A, B, C) and Class II (DR, DQ) match 
with the recipient, most patients requiring transplantation 
do not have a readily available donor. Siblings are the usual 
source of donors, being the only available matched family 
members. Today, with smaller families, only about 10% of 
patients have an HLA-matched donor.  There is a 5% chance 
of finding a suitable donor in the extended family, e.g. cousins.
Transplantation with 1-locus or even 2-loci mismatches from 
a family donor can be performed, but the risks of graft failure 
and GVHD increase. Haplo-identical transplants from parents 
to children play a role when no donor is available but are risky.
Owing to this lack of donors, and the expansion of allogeneic 
stem cell transplantation in malignant and non-malignant 
diseases, an alternative source of donors had to be found. 
Matched-unrelated-donor stem cell 
donors 
Two alternative non-family sources of stem cells are now used, 
namely matched unrelated donor (MUD) transplants and 
umbilical cord blood transplants.10 
MUD registries have grown in most developed countries. 
Racially homogenous societies such as Scandinavia lend 
themselves best to such registries, as HLA genes are largely 
ethnically based. Most European registries have donors of 
Caucasian origin, making access to donors of Asian and African 
origin difficult to obtain. The ethnically diverse population of 
the USA is the best source of donors throughout the world, but 
high costs and strict National Marrow Donor Program (NMDP) 
regulations limit international access to US donors. The 
NMDP has developed a network of co-operative registries as 
an alternative form of access to donors. In August 2006 South 
Africa signed a co-operative agreement between the NMDP 
and the South African Bone Marrow Registry (SABMR). 
Donor registries co-operate and their linked databases enable 
patients to have access to donors worldwide. At the time of 
writing in December 2007 there were 59 stem cell registries and 
40 cord blood registries worldwide with access to 12.02 million 
registered donors.
Umbilical cord blood transplantation
Umbilical cord blood, the other alternative source of stem 
cells, is useful for children and for small adults (under 50 kg) 
and furthermore requires a less stringent HLA match.  Stored 
umbilical cord blood does not rely on donor presence and 
current good health. Once cord blood has been shown to be 
HIV, hepatitis B and C virus-free, the donor is guaranteed. 
Living MUDs may change their minds, move town, die or 
seroconvert. The HIV epidemic, limited resources and lack of 
government support have resulted in few moves to develop 
umbilical cord banking in South Africa.
Bone marrow transplantation in South 
Africa
Bone marrow transplantation in South Africa was developed 
at the University of Cape Town from the mid-1970s, and the 
University of the Witwatersrand in the 1980s. 
South African Bone Marrow Registry (SABMR)
The SABMR was started at University of Cape Town by 
Professor Ernette du Toit with help from Professor Peter Jacobs 
in early 1990s.  It is a non-profit organisation (Reg. No. 004-300 
NPO) that co-ordinates the provision of matched unrelated 
stem cell donors for South Africa, and is the contact for 
countries seeking unrelated donors in South Africa. 
The SABMR was established in the Laboratory for Tissue 
Immunology (LTI) in Cape Town. This was an extension of 
the LTI functions, which was initially HLA typing for organ 
transplantation since Chris Barnard’s first heart transplants in 
1960s. The European Federation for Immunogenetics accredited 
the LTI as an HLA-typing centre for unrelated marrow 
transplantation in 1999.
The first donors were recruited in 1991. By May 1992 there 
were 210 donors on the registry, and by 1993 there were 534, of 
which 482 were HLA-ABDR typed. Owing to lack of funding 
and donor awareness, the SABMR grew more slowly for the 
next 7 years. Donor awareness was increased with the help of 
the Natal Blood Transfusion Service (NBTS) and two donor 
funding organisations, the Darren Serebro Foundation in 
Gauteng and the Sunflower Fund in Western Cape. The Darren 
Serebro Foundation, which started in August 1998, recruited 
over 20 000 donors, mainly in Gauteng. The Sunflower Fund 
formed in 1999 was inspired by the struggles of Chris Corlett 
and Darren Serebro against leukaemia. The aim of the two 
organisations is to rally financial support to increase the 
number of stem cell donors in South Africa. The Sunflower 
Fund now has the national responsibility for raising funds 
for tissue typing of unrelated donors, which had resulted in 
an increase in the SABMR donor database size to 63 123 by 
December 2007 (Fig. 1).
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In the worldwide database of over 12 million, 70% are HLA-
ABDR typed.  Unfortunately only 6% of the potential SABMR 
donors have been HLA-DR typed (Fig. 1). This deficiency is 
now being addressed by the SABMR.
Lack of black donors makes MUD transplantation 
problematic in South Africa, with very few recipients of African 
origin. This problem is exacerbated by the lack of donors of 
African origin on European registries available to South African 
patients. The NMDP is a potential source of donors of African 
origin, although African-Americans are mainly of West African 
origin with different HLA typing frequencies to southern 
African blacks. 
Following the recruitment of the first donors, the World 
Marrow Donor Association (WMDA) recognised the SABMR 
as the HUB centre for South Africa in September 1991. The 
WMDA is a voluntary organisation of representatives of blood 
stem cell donor registries, cord blood banks, other organisations 
and individuals with an interest in haematopoietic stem cell 
transplantation. It provides a forum for discussion of issues 
regarding the clinical use of haematopoietic stem cells from 
unrelated donors across international boundaries and for 
formulation of guidelines on logistics, quality control, ethics, 
finances, information technology and registry accreditation. 
Bone Marrow Donors Worldwide (BMDW) situated in 
Leiden, The Netherlands, is a voluntary collaborative effort of 
stem cell donor registries. BMDW collates donor information 
worldwide. This database contains details of over 12 million 
donors, including more than 63 000 from South Africa, and is 
available online to all participating registries. This allows all 




The first MUD transplant in South Africa was performed at 
the now University of the Witwatersrand Donald Gordon 
Medical Centre in Johannesburg in June 1997. Bone marrow 
was harvested in Belgium and flown to Johannesburg. In 1999 
the first SABMR donor provided peripheral blood stem cells 
to a South African patient. In 2003 the first black South African 
donor provided stem cells for an unrelated patient and the 
first unrelated cord blood transplant was performed.  At the 
time of writing, a total of 125 patients had received first MUD 
transplants in Gauteng and the Western Cape (Fig. 2). Of the 
donors 32 were from the SABMR and 93 from international 
registries, mainly in Europe (of the latter 6 were cord bloods).  
In addition 7 SABMR donors supplied stem cells to patients 
in Germany, Italy, Portugal, The Netherlands, the UK and the 
USA.   
Conclusions
Allogeneic bone marrow and now peripheral blood stem 
cell transplantation has become an important treatment of 
haematological malignancies, first acute and chronic myeloid 
leukaemia and now myelodysplasia, lymphomas and even 
multiple myeloma. Its role in chronic myeloid leukaemia has 
diminished considerably since the advent of imatinib.11 
It also plays an important role in non-malignant 
haematological diseases, first aplastic anaemia and now 
haemoglobinopathies, thalassaemias and storage diseases. 
Modern tissue typing and immunosuppression, and better 
supportive care including newer antibiotics, antifungal and 
antiviral agents, have reduced mortality and morbidity. 
Alternative sources of stem cells, including MUD and 
umbilical cord blood transplantation, have widened the 
availability of donors throughout the world. The growth and 
development of the SABMR is essential in our quest for donors, 
especially for patients of black African origin, and needs 
support from the public, donor funds, universities, private 
corporations and the government. 
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Year of MUD Transplant
Table 2: Number of South African Patients receiving MUD BMT
(first transplant only) n = 125
Fig. 2. Number of South African patients receiving MUD transplants 









Table 1: Number of SABMR donors per year - Total vs ABDR
TOTAL
HLA-ABDR
Fig. 1. Number of SABMR donors per year – total versus ABDR typed
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